Roche Holding AG (XSWX:RO) Accounts Payable: CHF4,237 Mil (As of Dec. 2025)


XSWX:RO Roche Holding AG XSWX:RO
77 GF Score
Price CHF342.00
GF Value CHF269.42
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roche Holding AG Accounts Payable?

Roche Holding AG XSWX:RO -0.47% 77 Accounts Payable is CHF4,237 Mil as of Dec. 2025. GuruFocus rates XSWX:RO with a GF Score™ of 77/100 and a GF Value™ of CHF269.42 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Roche Holding AG's Accounts Payable for the quarter that ended in Dec. 2025 was CHF4,237 Mil.

Roche Holding AG's quarterly Accounts Payable increased from Dec. 2024 (CHF3,984 Mil) to Jun. 2025 (CHF4,512 Mil) but then declined from Jun. 2025 (CHF4,512 Mil) to Dec. 2025 (CHF4,237 Mil).

Roche Holding AG's annual Accounts Payable increased from Dec. 2023 (CHF3,524 Mil) to Dec. 2024 (CHF3,984 Mil) and increased from Dec. 2024 (CHF3,984 Mil) to Dec. 2025 (CHF4,237 Mil).

Roche Holding AG Accounts Payable Related Terms

Roche Holding AG Accounts Payable Historical Data

* Premium members only.

The historical data trend for Roche Holding AG's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roche Holding AG Accounts Payable Chart

Roche Holding AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,844.00 3,861.00 3,524.00 3,984.00 4,237.00

Roche Holding AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,524.00 3,994.00 3,984.00 4,512.00 4,237.00
XSWX:RO
77GF Score
Roche Holding AG XSWX:RO
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roche Holding AG Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of CHF4,237 Mil mean?
Roche Holding AG (XSWX:RO) has a Accounts Payable of CHF4,237 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Roche Holding AG and its competitors.
Is Roche Holding AG's Accounts Payable too high?
Roche Holding AG's current Accounts Payable is CHF4,237 Mil. Overall, Roche Holding AG has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's Accounts Payable compare to LLY and JNJ?
Roche Holding AG's Accounts Payable of CHF4,237 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Roche Holding AG and its competitors. Roche Holding AG's current Accounts Payable is CHF4,237 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:RO) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF269.42, compared to a current price of CHF342.00 — trading 26.9% above its estimated fair value. The current Accounts Payable is CHF4,237 Mil. Roche Holding AG's overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Roche Holding AG (XSWX:RO), the current Accounts Payable is CHF4,237 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Roche Holding AG (XSWX:RO) Overvalued in 2026?

Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued. The current stock price of CHF342.00 is trading 26.9% above its estimated GF Value™ of CHF269.42. GuruFocus considers Roche Holding AG to be Modestly Overvalued.

Key valuation signals for XSWX:RO:

  • Accounts Payable: CHF4,237 Mil
  • GF Value™: CHF269.42 vs. price of CHF342.00 (26.9% above fair value)
  • GF Score™: 77/100 with 7 warning signs

No single metric tells the full story. See the XSWX:RO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roche Holding AG Business Description

Address Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
77GF Score

Get the complete analysis for XSWX:RO

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF342.00
Price
CHF269.42
GF Value